Wave Life Sciences Ltd. - Ordinary Shares (WVE): Price and Financial Metrics
GET POWR RATINGS... FREE!
WVE POWR Grades
- WVE scores best on the Quality dimension, with a Quality rank ahead of 64.02% of US stocks.
- The strongest trend for WVE is in Stability, which has been heading up over the past 179 days.
- WVE ranks lowest in Momentum; there it ranks in the 12th percentile.
WVE Stock Summary
- Revenue growth over the past 12 months for Wave Life Sciences Ltd comes in at 104.03%, a number that bests 92.18% of the US stocks we're tracking.
- The volatility of Wave Life Sciences Ltd's share price is greater than that of 91.57% US stocks with at least 200 days of trading history.
- Wave Life Sciences Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -43.69%, greater than the shareholder yield of only 9.85% of stocks in our set.
- Stocks that are quantitatively similar to WVE, based on their financial statements, market capitalization, and price volatility, are MEIP, PLRX, GLYC, EIGR, and SQZ.
- Visit WVE's SEC page to see the company's official filings. To visit the company's web site, go to www.wavelifesciences.com.
WVE Valuation Summary
- In comparison to the median Healthcare stock, WVE's EV/EBIT ratio is 104.78% lower, now standing at -1.4.
- WVE's price/sales ratio has moved down 2247.9 over the prior 71 months.
- Over the past 71 months, WVE's price/sales ratio has gone down 2247.9.
Below are key valuation metrics over time for WVE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| WVE | 2021-08-31 | 20.5 | 14.7 | -2.2 | -1.4 |
| WVE | 2021-08-30 | 19.7 | 14.1 | -2.2 | -1.3 |
| WVE | 2021-08-27 | 19.3 | 13.8 | -2.1 | -1.3 |
| WVE | 2021-08-26 | 18.6 | 13.4 | -2.0 | -1.2 |
| WVE | 2021-08-25 | 19.2 | 13.8 | -2.1 | -1.3 |
| WVE | 2021-08-24 | 19.4 | 13.9 | -2.1 | -1.3 |
WVE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- WVE has a Quality Grade of C, ranking ahead of 33.55% of graded US stocks.
- WVE's asset turnover comes in at 0.06 -- ranking 311th of 680 Pharmaceutical Products stocks.
- IONS, CORT, and CPIX are the stocks whose asset turnover ratios are most correlated with WVE.
The table below shows WVE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.060 | 1 | -4.284 |
| 2021-03-31 | 0.061 | 1 | -4.798 |
| 2020-12-31 | 0.078 | 1 | -7.715 |
| 2020-09-30 | 0.050 | 1 | -5.619 |
| 2020-06-30 | 0.047 | 1 | -5.196 |
| 2020-03-31 | 0.055 | 1 | -4.843 |
WVE Price Target
For more insight on analysts targets of WVE, see our WVE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.86 | Average Broker Recommendation | 1.64 (Moderate Buy) |
WVE Stock Price Chart Interactive Chart >
WVE Price/Volume Stats
| Current price | $2.79 | 52-week high | $7.24 |
| Prev. close | $2.90 | 52-week low | $1.16 |
| Day low | $2.79 | Volume | 5,311 |
| Day high | $2.79 | Avg. volume | 422,807 |
| 50-day MA | $1.84 | Dividend yield | N/A |
| 200-day MA | $3.02 | Market Cap | 170.88M |
Wave Life Sciences Ltd. - Ordinary Shares (WVE) Company Bio
WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company was founded in 2012 and is based in Simgapore.
Latest WVE News From Around the Web
Below are the latest news stories about Wave Life Sciences Ltd that investors may wish to consider to help them evaluate WVE as an investment opportunity.
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, March 3, 2022, to discuss its fourth quarter and full year 2021 financial results and provide a business update. The webcast of the conference call may be accessed by vi |
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue EstimatesAdaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 5.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 10:40 a.m. ET. A live webcast o |
Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of OligonucleotidesWave paper on PN chemistry for silencing in the CNS, and the implications for oligonucleotides more broadly, designated as a Breakthrough Article by Nucleic Acids Research Publications highlight the profound impact of PN chemistry on potency, distribution, and durability of effect in multiple preclinical models and across modalities; underscore the potential of Wave’s ongoing clinical programs and pipeline, all of which utilize PN chemistry First clinical data for PN chemistry-containing stereop |
Two Organizations To Support Wave Life Sciences' FTD, ALS ProgramThe Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) will support Wave Life Sciences Ltd's (NASDAQ: WVE) amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) program. The organizations will support the Company's FOCUS-C9 Phase 1b/2a trial of WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD) and amyotrophic lateral sclerosis (C9-ALS). The partnership provides an investment from A |
WVE Price Returns
| 1-mo | 99.29% |
| 3-mo | 37.44% |
| 6-mo | -11.15% |
| 1-year | -58.11% |
| 3-year | -89.57% |
| 5-year | -85.00% |
| YTD | -11.15% |
| 2021 | -60.10% |
| 2020 | -1.81% |
| 2019 | -80.93% |
| 2018 | 19.77% |
| 2017 | 34.23% |
Continue Researching WVE
Want to see what other sources are saying about Wave Life Sciences Ltd's financials and stock price? Try the links below:Wave Life Sciences Ltd (WVE) Stock Price | Nasdaq
Wave Life Sciences Ltd (WVE) Stock Quote, History and News - Yahoo Finance
Wave Life Sciences Ltd (WVE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...